Eiger BioPharmaceuticals Stock Price. Everything You Need To Know About The Eiger BioPharmaceuticals Stock!
Eiger BioPharmaceuticals, Inc. is a company focused on developing and commercializing foundational therapies for Hepatitis Delta Virus. Headquartered in Palo Alto, California, the company employs 56 full-time employees and went IPO on 2014-01-30.
The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. The company’s clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI), and Avexitide in Post-Bariatric Hypoglycemia (PBH).
Eiger BioPharmaceuticals’ approved product, Zokinvy (lonafarnib), is used to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome (HGPS) and to treat processing-deficient Progeroid Laminopathies (PL).
Lonafarnib (LNF) is an orally bioavailable farnesylation inhibitor in a phase III clinical trial for HDV infection and is the company’s lead program. Peginterferon Lambda (lambda) is its second program in clinical development for HDV and Covid-19, currently in phase III.
As a company focused on developing and commercializing foundational therapies for Hepatitis Delta Virus, Eiger BioPharmaceuticals is well-positioned to meet the growing demand for treatments for this condition. It is important to stay up to date with industry trends and developments to make informed decisions. Monitoring premarket trends and staying informed on stocks share price today and market cap can provide valuable insights for investors looking to stay ahead of the curve. By researching companies like Eiger BioPharmaceuticals and staying informed on their operations and developments, investors can gain valuable insights into the company’s financial health and make informed decisions about whether to invest in the company or not.
Eiger BioPharmaceuticals Stock Price. Everything You Need To Know About The Eiger BioPharmaceuticals Stock! performance
- Employees 56
- Company HQ Palo Alto
- Website https://www.eigerbio.com/
- Asset Type
- Market Capitalization 0
- Earnings Per Share
- Dividends Per Share
- Dividend Date
- Quarterly Earnings Growth
Looking to invest in Eiger BioPharmaceuticals from Malaysia, Thailand, Indonesia, or Vietnam? You’re in the right place! Eiger BioPharmaceuticals is a cutting-edge biopharmaceutical company focused on developing innovative therapies for serious rare and ultra-rare diseases. With their commitment to transforming the lives of patients around the world, investing in Eiger BioPharmaceuticals can be a strategic move for retail investors. At Zorion, we provide investment insights and recommendations, helping you make informed decisions. Our platform offers access to real US stocks and Pre-IPO companies, ensuring you have diverse investment options. Additionally, we provide comprehensive educational resources to help you enhance your investment knowledge. Start investing in Eiger BioPharmaceuticals today and be a part of driving advancements in healthcare.
